Pattern of missing probes in rifampicin resistant TB by Xpert MTB/RIF assay at a tertiary care centre in Mumbai

Ramaswamy, 1998, Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update, Tuber Lung Dis, 79, 3, 10.1054/tuld.1998.0002 World Health Organization, 2014 Central TB Division, Ministry of Health and Family Welfare, 2018 Udwadia, 2012, Totally drug resistant tuberculosis in India, Clin Infect Dis, 54, 579, 10.1093/cid/cir889 Grosset, 1978, The sterilizing value of rifampicin and pyrazinamide in experimental short-course chemotherapy, Bull Int Union Tuberc, 53, 5 Jarlier, 1994, Mycobacterial cell wall: structure and role in natural resistance to antibiotics, FEMS Microbiol Lett, 123, 11, 10.1111/j.1574-6968.1994.tb07194.x Telenti, 1993, Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis, Lancet, 341, 647, 10.1016/0140-6736(93)90417-F Lawn, 2011, Xpert ® MTB/RIF Assay: development, evaluation implementation of a new rapid molecular diagnostic for tuberculosis and rifampicin resistance, Future Microbiol, 6, 1067, 10.2217/fmb.11.84 World Health Organization. Geneva, Switzerland. Policy Update, 2013 Mokrousov, 2004, Multicenter evaluation of reverse line blot assay for detection of drug resistance in Mycobacterium tuberculosis clinical isolates, J Microbiol Methods, 57, 323, 10.1016/j.mimet.2004.02.006 Cepheid – Xpert MTB/RIF Training Manual. World Health Organization, 2016 Reddy, 2017, Molecular epidemiology of rifampicin resistance in Mycobacterium tuberculosis using the GeneXpert MTB/RIF assay from a rural setting in India, J Pathogens, 2017, 5, 10.1155/2017/6738095 Irfan, 2016, Rifampicin resistance mutations in the 81 bp RRDR of rpoB gene in Mycobacterium tuberculosis clinical isolates using Xpert MTB/RIF in Khyber Pakhtunkhwa, Pakistan: a retrospective study, BMC Infect Dis, 16, 413, 10.1186/s12879-016-1745-2 Yue, 2003, Mutations in the rpoB gene of multidrug-resistant Mycobacterium tuberculosis isolates from China, J Clin Microbiol, 41, 2209, 10.1128/JCM.41.5.2209-2212.2003 Mboowa, 2014, Rifampicin resistance mutations in the 81 bp RRDR of rpoB gene in Mycobacterium tuberculosis clinical isolates using Xpert MTB/RIF in Kampala, Uganda: a retrospective study, BMC Infect Dis, 14, 481, 10.1186/1471-2334-14-481 Billington, 1999, Physiological cost of rifampin resistance induced in vitro in Mycobacterium tuberculosis, Antimicrob Agents Chemother, 43, 1866, 10.1128/AAC.43.8.1866 Rufai, 2014, Comparison of Xpert MTB/RIF with line probe assay for detection of rifampin monoresistant Mycobacterium tuberculosis, J Clin Microbiol, 52, 1846, 10.1128/JCM.03005-13 Sirgel, 2013, The rationale for using rifabutin in the treatment of MDR and XDR tuberculosis outbreaks, PLoS One, 8, e59414, 10.1371/journal.pone.0059414 Köser, 2012, Importance of the genetic diversity within the Mycobacterium tuberculosis complex for the development of novel antibiotics and diagnostic tests of drug resistance, Antimicrob Agents Chemother, 56, 6080, 10.1128/AAC.01641-12 Gupta, 2014, Association of MDR-TB isolates with clinical characteristics of patients from Northern region of India, Indian J Med Microbiol, 32, 270, 10.4103/0255-0857.136561 Kaur, 2016, Epidemiology of rifampicin resistant tuberculosis and common mutations in rpoB gene of Mycobacterium tuberculosis: a retrospective study from six districts of Punjab (India) using Xpert MTB/RIF assay, J Lab Phys, 8, 96 Mani, 2001, Mutations in the rpoB gene of multidrug resistant Mycobacterium tuberculosis clinical isolates from India, J Clin Microbiol, 39, 2987, 10.1128/JCM.39.8.2987-2990.2001 Nwokoye, 2014, Non-conforming rifampicin susceptibility test reports from Xpert MTB/RIF assay: the national reference laboratory experience in Nigeria, Open Sci J Clin Med, 2, 59